| dc.contributor.author | Pardo-Moreno, Teresa | |
| dc.contributor.author | García Morales, Victoria | |
| dc.contributor.author | Suleiman-Martos, Sami | |
| dc.contributor.author | Rivas-Domínguez, Antonio | |
| dc.contributor.author | Mohamed-Mohamed, Himan | |
| dc.contributor.author | Ramos Rodríguez, Juan José | |
| dc.contributor.author | Melguizo-Rodríguez, Lucía | |
| dc.contributor.author | González-Acedo, Anabel | |
| dc.contributor.other | Biomedicina, Biotecnología y Salud Pública | es_ES |
| dc.date.accessioned | 2024-05-30T10:35:02Z | |
| dc.date.available | 2024-05-30T10:35:02Z | |
| dc.date.issued | 2023 | |
| dc.identifier.issn | 1999-4923 | |
| dc.identifier.uri | http://hdl.handle.net/10498/32443 | |
| dc.description.abstract | Parkinson’s disease (PD) is a neurodegenerative pathology, the origin of which is associated
with the death of neuronal cells involved in the production of dopamine. The prevalence of PD has
increased exponentially. The aim of this review was to describe the novel treatments for PD that are
currently under investigation and study and the possible therapeutic targets. The pathophysiology
of this disease is based on the formation of alpha-synuclein folds that generate Lewy bodies, which
are cytotoxic and reduce dopamine levels. Most pharmacological treatments for PD target alphasynuclein
to reduce the symptoms. These include treatments aimed at reducing the accumulation
of alpha-synuclein (epigallocatechin), reducing its clearance via immunotherapy, inhibiting LRRK2,
and upregulating cerebrosidase (ambroxol). Parkinson’s disease continues to be a pathology of
unknown origin that generates a significant social cost for the patients who suffer from it. Although
there is still no definitive cure for this disease at present, there are numerous treatments available
aimed at reducing the symptomatology of PD in addition to other therapeutic alternatives that are
still under investigation. However, the therapeutic approach to this pathology should include a
combination of pharmacological and non-pharmacological strategies to maximise outcomes and
improve symptomatological control in these patients. It is therefore necessary to delve deeper into
the pathophysiology of the disease in order to improve these treatments and therefore the quality of
life of the patients. | es_ES |
| dc.format | application/pdf | es_ES |
| dc.language.iso | eng | es_ES |
| dc.publisher | MDPI | es_ES |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
| dc.source | Pharmaceutics - 2023, Vol. 15 n. 3 pp. 1-24 | es_ES |
| dc.subject | alpha-synuclein | es_ES |
| dc.subject | Lewy bodies | es_ES |
| dc.subject | Parkinson’s disease | es_ES |
| dc.subject | therapeutic targets | es_ES |
| dc.title | Current Treatments and New, Tentative Therapies for Parkinson’s Disease | es_ES |
| dc.type | journal article | es_ES |
| dc.rights.accessRights | open access | es_ES |
| dc.identifier.doi | 10.3390/PHARMACEUTICS15030770 | |
| dc.relation.projectID | info:eu-repo/grantAgreement/AEI//PID2019-110960GB-I00 | es_ES |
| dc.relation.projectID | info:eu-repo/grantAgreement/Junta de Andalucía//P18-RT-3324 | es_ES |
| dc.relation.projectID | info:eu-repo/grantAgreement/Junta de Andalucía//P20-01293 | es_ES |
| dc.relation.projectID | info:eu-repo/grantAgreement/Junta de Andalucía//P20-01061 | es_ES |
| dc.type.hasVersion | VoR | es_ES |